Bøtker Simon, Birn Henrik, Øzbay Lara Aygen
Department of Nephrology, Palle Juul-Jensens Blvd 99, Aarhus University Hospital, Aarhus 8000, Denmark.
Faculty of Health, Aarhus University, Aarhus, Denmark.
Case Rep Endocrinol. 2023 Jan 21;2023:3648178. doi: 10.1155/2023/3648178. eCollection 2023.
Systemically administered glucocorticoids constitute an essential part of the immunosuppressive regimen for transplant recipients, yet their known risks of causing hyperglycemia or posttransplant diabetes require close monitoring and minimisation of use, when possible, to prevent detrimental effects on patient morbidity and graft survival. Topical glucocorticoids, on the other hand, are rarely considered to affect glucose metabolism and therefore seldomly monitored, despite their wide and in some cases, long-term use. We report a case of a renal transplant recipient presenting with acute hyperosmolar hyperglycemia after treatment with topical glucocorticoids and present a mini review of the literature.
全身应用糖皮质激素是移植受者免疫抑制方案的重要组成部分，然而其已知的导致高血糖或移植后糖尿病的风险需要密切监测，并在可能的情况下尽量减少使用，以防止对患者发病率和移植物存活产生不利影响。另一方面，局部用糖皮质激素很少被认为会影响糖代谢，因此尽管其使用广泛，在某些情况下甚至长期使用，但很少受到监测。我们报告一例肾移植受者在局部应用糖皮质激素治疗后出现急性高渗性高血糖的病例，并对相关文献进行简要综述。
